RPL11 and acute kidney injury: To date, although no studies have directly investigated RPL11 in AKI, its demonstrated pharmacological activities—including modulation of cell proliferation, apoptosis, inflammation, and immune responses in injury and oncology and Diamond-Blackfan anemia—provide crucial theoretical support for exploring its potential protective mechanisms in AKI.